Study of the gut microbiome as a novel target for prevention of hospital-associated infections in intensive care unit patients

Suzan Ahmed Elfiky; Shwikar Mahmoud Ahmed; Ahmed Mostafa Elmenshawy; Gehad Mahmoud Sultan; Sara Lotfy Asser

doi:10.4266/acc.2022.01116

Articles

Page Path: HOME > Acute Crit Care > Volume 38(1); 2023 > Article

Original Article Infection Study of the gut microbiome as a novel target for prevention of hospital-associated infections in intensive care unit patients: Suzan Ahmed Elfiky¹, Shwikar Mahmoud Ahmed¹, Ahmed Mostafa Elmenshawy², Gehad Mahmoud Sultan¹, Sara Lotfy Asser¹; Acute and Critical Care 2023;38(1):76-85.
DOI: https://doi.org/10.4266/acc.2022.01116
Published online: February 23, 2023

¹Department of Medical Microbiology and Immunology, Faculty of Medicine, University of Alexandria, Alexandria Governorate, Egypt

²Department of Critical Care Medicine, Faculty of Medicine, Alexandria University, Egypt

Corresponding author: Gehad Mahmoud Sultan Department of Medical Microbiology and Immunology, Faculty of Medicine, Alexandria University, Alexandria, Egypt Tel: +20-12-2835-1979 Email: gehad.soltan@alexmed.edu.eg

• Received: August 25, 2022 • Revised: November 23, 2022 • Accepted: November 23, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,089 Views
140 Download
3 Web of Science
3 Crossref
1 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
KEY MESSAGES
NOTES
Acknowledgments
REFERENCES

Abstract

Background
Hospital-acquired infections (HAIs) are increasing due to the spread of multi-drug-resistant organisms. Gut dysbiosis in an intensive care unit (ICU) patients at admission showed an altered abundance of some bacterial genera associated with the occurrence of HAIs and mortality. In the present study, we investigated the pattern of the gut microbiome in ICU patients at admission to correlate it with the development of HAIs during ICU stay.
Methods
Twenty patients admitted to an ICU with a cross-matched control group of 30 healthy subjects of matched age and sex. Quantitative SYBR green real-time polymerase chain reaction was done for the identification and quantitation of selected bacteria.
Results
Out of those twenty patients, 35% developed ventilator-associated pneumonia during their ICU stay. Gut microbiome analysis showed a significant decrease in Firmicutes and Firmicutes to Bacteroidetes ratio in ICU patients in comparison to the control and in patients who developed HAIs in comparison to the control group and patients who did not develop HAIs. There was a statistically significant increase in Bacteroides in comparison to the control group. There was a statistically significant decrease in Bifidobacterium and Faecalibacterium prausnitzii and an increase in Lactobacilli in comparison to the control group with a negative correlation between Acute Physiology and Chronic Health Evaluation (APACHE) II score and Firmicutes to Bacteroidetes and Prevotella to Bacteroides ratios.
Conclusions
Gut dysbiosis of patients at the time of admission highlights the importance of identification of the microbiome of patients admitted at the ICU as a target for preventing of HAIs.
Key Words: 16S ribosomal RNA; dysbiosis; gut microbiome; healthcare-associated infections; intensive care unit; quantitative real-time polymerase chain reaction

INTRODUCTION

Hospital-acquired infections (HAIs) are increasing in frequency due to the spread of multi-drug resistant organisms which abraded the ability of any healthcare setting to treat such these infections [1]. Healthcare facilities could not depend on traditional infection control measures only. Recent clinical trials settled many protocols to be used in the intensive care unit (ICU) to modulate the microbiome to prevent or treat infections [1-3].

The gut microbiome plays vital roles in digestion, synthesis of vitamins, drug metabolism, protection from infection, and recovery from illness. A balanced gut microbiome increases the host's defense against infection by regulating the local and systemic immune system, inhibiting the growth of enteric pathogens plus supporting epithelial barrier integrity required for the protection against the systemic dissemination of pathogens [4,5]. Several studies reported that dysbiosis in patients in the ICU may increase their susceptibility to healthcare-associated infections and poor outcomes [6-9]. Probiotics replacements has been proposed as a promising treatment to preserve gut integrity and arrest the loss of intestinal epithelial barrier function that is linked to sepsis and systemic inflammatory response syndrome [10].

The use of probiotics as a preventive measure has shown to have promising effects in many studies to avoid infection and to improve recovery in ICU patients, whereas the use of prophylactic antibiotics has been linked to a rise in antibiotic resistance in addition to its high cost [11]. Recently, probiotic studies got the directions of characterization of the actual ICU dysbiosis using microbiome profiling and personalize the ideal probiotic therapies to be administered [12]. Characterizing ICU microbiome changes could be crucial for directing the establishment of probiotic and symbiotic diagnostic and therapeutic approaches using microbiome profiles. Because of this evidence and considerations, the present study aims to describe the gut microbiome profile in ICU patients and to correlate it to the development of HAIs.

MATERIALS AND METHODS

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Institutional Research Committee of Medical Research Ethics Committee of Alexandria Faculty of Medicine, Egypt (No. 00012098) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from each individual or a competent charged person in case of the patient's incompetence for inclusion in the study.

Patients

The study was conducted on 20 ICU patients admitted for noninfectious causes to the ICU. They were followed up during their stay in the ICU for the development of HAIs or not. A cross-matching control group of 30 healthy subjects of similar age and sex were also included. We included all adult patients admitted to the ICU without specific diagnosis as the ICUs serve a mixed population of medical, trauma, toxicological and neurologic patients.

Our exclusion criteria were chosen to cover several conditions that can independently affect the gut microbiota including: (1) severe chronic liver impairment (including liver cirrhosis, hepatic fibrosis, end-stage liver diseases or hepatocellular carcinoma); (2) chronic renal impairment (chronic kidney disease); abnormalities of kidney function or structure present for more than 3 months) including patients with end stage renal disease; (3) inflammatory bowel diseases including Crohn disease and ulcerative colitis; (4) patients with diabetes mellitus as well as known immunodeficiency (e.g., leukemic patients, patients on steroids, oncology patients receiving chemotherapy); (5) patients with sepsis from the start; (6) patients with the previous admission within 6 months; and (7) before intake of antibiotics.

History and Clinical Data

A detailed history was taken from patients and controls. All patients and controls were subjected to full clinical examination. Body weight and height were measured, and body mass index (BMI) was calculated. All patients underwent physical examination and assessment of medical device usage, including mechanical ventilators, urinary catheters, and peripheral or central venous catheters.

Laboratory Investigations

The Acute Physiology and Chronic Health Evaluation (APACHE) II score was calculated upon admission for precise information on the patient's acute severity of illness and predicting hospital mortality among critically ill adults. Each of the 12 variables is translated into weights using the original APACHE score and helps to stratify a patient's risks [13]. These variables include: (1) temperature (rectal ° C), (2) mean arterial blood pressure (mm Hg), (3) pulse, (4) respiratory rate (ventilated or not ventilated), (5) oxygenation (FiO₂ ≥0.5 or FiO₂ <0.5), (6) arterial pH, (7) serum sodium level (mmol/L), (8) serum potassium level (mMol/L), (9) serum creatinine (mg/100 ml), (10) hematocrit %, (11) white blood cell (×10³/µl), and (12) Glasgow coma score.

Gut Microbiome Analysis

Sample collection, preservation, and transport

Stool samples were collected from controls, kept at –20 °C upon defecation at home, and delivered frozen to the main microbiology laboratory. For the ICU patients, the stool samples were collected within 72 hours after admission (before antibiotic treatment), and at once transferred to the lab. All the samples were stored at −80 °C for further processing.

DNA extraction

DNA was extracted from 180 mg stool samples using Biamp Fast DNA Stool Extraction Mini Kit (Qiagen). The resulting DNA extracts were stored at –80 °C until polymerase chain reaction (PCR) analysis.

SYBR green real-time PCR

Oligonucleotide primers targeted the 16S ribosomal RNA (rRNA) gene sequences of selected phyla, genera, or species constituting the gut microbiota (Bacteroides, Prevotella, Ruminococcus, Bacteroidetes, Firmicutes, Bifidobacterium, Lactobacillus, Akkermansia muciniphila, Faecalibacterium prausnitzii, and Clostridioides difficile). Universal bacterial primers were used to determine the total bacteria in the DNA extract, the amplification of which served as the denominator against which the amplification of the other bacteria was compared. Specific bacterial DNA was expressed relative to the total (universal) bacteria DNA in the stool samples by the RQ software (Qiagen). All primers (Invitrogen) used in the study were previously described and are listed in Table 1 [14].

Detection and Quantitation

Amplification was performed in a light cycler (Rotor-Gene Q, Qiagen) using a SensiFAST TM SYBR No-ROX PCR kit (Bioline Co.). In short, forward and reverse primers (4 pmol each) were used in 20 μl reactions having 2 μl of the DNA extract. PCR amplification was performed with an initial denaturation at 95 °C for 10 minutes, followed by 40 cycles of denaturation at 95 °C for 30 seconds, annealing at 60 °C for 30 seconds, and extension at 72 °C for 30 seconds. Melting curve analysis was performed to check the specificity of the amplified products. Quantitation of specific bacterial DNA was expressed as relative quantitation (the cycle threshold [Ct] at which DNA for a specific target was detected relative to the Ct at which universal bacterial DNA was detected). This relative quantification is calculated automatically by the Rotor-Gene software and expressed as a relative fold difference [15]. The enterotype of all participants was figured out according to the dominant bacteria present in the three bacteria: Bacteroides (Enterotype 1), Prevotella (Enterotype 2), or Ruminococcus (Enterotype 3).

Statistical Analysis of the Data

Data entry and analysis were carried out using the IBM SPPS ver. 20 (IBM Corp.) [16]. Spearman correlation coefficient was calculated for assessing correlation. All results were interpreted at a 5% level of significance where the difference between the study groups is considered significant if P ≤0.05. The Shannon diversity index is used to measure alpha diversity within the sample [17]. The Bray-Curtis similarity index was used to evaluate the degree of similarity between patients and controls [18].

RESULTS

Characteristics of the Participants

Demographic and clinical data of cases

Demographic data showed that out of the 20 patients admitted to the ICU, 8 patients were males, and 12 patients were female with male to female ratio of 2:3. Their mean and standard deviation (SD) age was 51.85±22.73 years, and their age ranged from 18 to 80 years. The BMI ranged between 24.69 and 34.89 kg/m² with a mean of 28.27±2.90 (Table 2). For the cross-matched control subjects, 13 were males, and 17 were females with male to female ratio of 1:1.3. Their mean age was 52.53±17.84 years, and their ages ranged from 23 to 81 years. The BMI ranged between 19.84 and 46.90 kg/m² with a mean of 28.77±5.31 kg/m² (Table 2). Among patients at the ICU, 14 patients (70%) had neurological insults; as shown in Table 2, three patients (15%) were with cardiopulmonary diseases while three patients (15%) with different medical conditions.

Regarding the APACHE II score, the mean was 13.25±4.56 ranging from 7.0 to 21.0. Out of the 20 ICU patients, 13 (65%) were on mechanical ventilation, 15 (75%) had a central venous catheter, and all with urinary catheters and peripheral intravenous catheters. Also, out of the 20 patients, 8 (40%) were fed through a nasogastric tube, 6 (30%) through an orogastric tube and 6 (30%) orally fed (Table 3).

During the patient's stay in the ICU and follow-up period, eight patients (40%) developed HAIs; seven of 20 (35%) Acinetobacter ventilator-associated pneumonia (VAP) and only one case of Staphylococcal bloodstream infection (BSI). All these cases were on mechanical ventilation and had a central venous catheter. Also, five of them (62.5%) were fed through a nasogastric tube and three (37.5%) through the orogastric tube (Table 3).

By comparing both subgroups of cases positive for hospital-associated infections (P-HAI) and negative for hospital-associated infections (N-HAI) about the APACHE score and ≥20% predicted mortality rate, it was higher in the P-HAI cases than N-HAI, but the difference was not statistically significant. There is a statistical difference between both subgroups regarding the number of devices specifically mechanical ventilation and the presence of central venous catheters (P<0.05).

Gut Microbiome Analysis

QQuantification of certain bacteria DNA was represented relative to the total amount of bacteria DNA found in the faeces sample rather than as an absolute number. The relative abundance values for the different bacteria were displayed as follows (4.75E-05 was used to represent 4.75 ×10^-5).

Phylum Level Analysis

Bacterial phylum analysis revealed that, although Bacteroidetes were increased, the difference was not statistically significant when compared to the control group, and ICU cases showed a statistically significant decline in Firmicutes (P=0.001). Firmicutes/Bacteroidetes (F/B) ratio in ICU cases was 0.03 compared to 1.44 in control subjects, a markedly lower ratio (P=0.008) (Table 4).

The same results were obtained when subgrouping ICU patients and comparing the subgroup of patients who developed HAIs and those negative for the HAIs subgroup. Both subgroups a statistically significant decrease in Firmicutes (P=0.001) in comparison to the control group and there was also a statistically significant difference between the two subgroups (Figure 1). As regards the Bacteroidetes, the developed HAIs subgroup cases showed no statistically significant difference compared to the control group and N-HAIs subgroup. The F/B ratio was statistically lower in the P-HAIs subgroup (0.31) compared to the N-HAIs subgroup (2.21) and the control group (1.44) (Table 5, Figure 1).

Patients who developed HAI were subdivided into patients who developed VAP and a patient with BSI, when comparing these patients there was not a significant difference between them in the gut microbiome composition while there was a significant difference regarding the F/B, Prevotella/Bacteroides (P/B) ratio or DSI.

Genus Level Analysis

Compared to the control group, ICU patients had a statistically significant increase in Bacteroides relative abundance (P=0.002) (Figure 1). As for Prevotella and Ruminococcus, there was a statistically significant difference between ICU patients and control cases (P=0.001). In comparison to the control group (0.26), the P/B ratio was significantly lower in the ICU patients (0.02) (Table 4).

For the two subgroups of ICU patients, both showed a lower relative abundance of Prevotella and Ruminococcus in comparison to the control group and there was no statistically significant difference between the two subgroups. On the other hand, the P-HAls subgroup showed a statistically significant higher relative abundance of Bacteroides compared to the control group while there was no statistically significant difference between the N-HAIs subgroup and the control group. Also, both subgroups showed a lower P/B ratio in comparison to the control group, however, there was no statistically significant difference between the two subgroups (Table 5).

According to the enterotype analysis, none of the 20 ICU patients had the enterotype 3 and just one (5% of them) had the enterotype 2. Of the 30 control participants, 18 (60%) were allocated to Enterotype 1, 9 (30%) to Enterotype 2, and 3 (10%) to Enterotype 3. Regarding the distribution of enterotypes, a statistically significant difference between the two groups was found (P=0.017) (Table 6), however, there was no statistically significant difference P-HAI and N-HAI subgroups (P=0.087).

Species Level Analysis

Regarding the beneficial bacteria, compared to the control group, ICU patients had statistically significant lower levels of Bifidobacteria (P=0.003) and F. prausnitzii (P=0.001) and higher levels of Lactobacilli (P=0.025). For Akkermansia muciniphila, there was no significant difference in A. muciniphila (P=0.828) between the two groups. As regards C. difficile, all the cases and control subjects were negative.

Correlation with Disease Severity and Mortality

There was a negative correlation between the APACHE score and F/B, and P/B ratios. When subgrouping ICU cases about mortality rate according to APACHE score; ≤20% and >20 % mortality rates. There was a significant decrease in the F/B ratio in patients with a mortality rate >20 % and those with ≤20 % mortality rate and between the F/B ratio in patients with a mortality rate >20 % and control (P₁=0.026 and P₃=0.001, respectively). P1 means P-value for comparing between <20% mortality and ≥20% mortality; P3 means P-value for comparing between ≥20% mortality and control.

Alpha Diversity

According to Shannon diversity index, which takes into account both species richness and evenness, the patients group's microbial diversity was statistically significantly lower than that of the control group (mean diversity index=1.16 vs. 1.46). The patient's P-HAIs and N-HAIs showed no statistically significant difference.

DISCUSSION

Gut microbiota composition alterations (dysbiosis) has been confirmed to occur not only in chronic diseases but also in acute illnesses [19]. Within hours of the commencement of serious illness, the density and makeup of the microbiota are significantly changed which promotes diseases and facilitates the occurrence of HAIs as it replaces the healthy microbiome [20]. There is growing data that suggests changes in the F/B ratio could be a marker of gut dysbiosis [21]. Firmicutes convert lactic acid to butyric acid, which induces mucin formation and so prevents leaky gut syndrome while Bacteroidetes, on the other hand, convert lactic acid to other short-chain fatty acids such as acetic acid, formic acid, or propionic acid that harm the gut lining. As a result, it is very important to maintain a larger percentage of butyrate-producing bacteria [22].

The altered F/B ratio has been correlated with different disease conditions such as obesity, asthma, and irritable bowel syndrome as well ICU mortality in critically ill patients [23,24]. A single-center prospective study includes twelve ICU patients and showed that changes in the gut microbiota can be linked to patient prognosis [25].

However, another study by Iapichino et al. [26] stated that low bacterial diversity was observed in both septic and non-septic patients, and discovered no links between the microbiota's diversity, the F/B ratio, or the ratio of Gram-positive to Gram-negative bacteria and outcome indicators like the occurrence of complications, infections, or mortality.

In our study, the gut microbiome profile of those patients who developed HAI mainly VAP had a statistically significant decrease in Firmicutes in comparison to the control group as well it was found the F/B ratio was statistically lower in the P HAIs subgroup (0.31) compared to N-HAIs subgroup (2.21) and the control group (1.44). VAP is an infectious inflammatory reaction of lung parenchyma that takes place after mechanical ventilation for greater than 48 hours. VAP affects between 5% and 40% of patients on invasive mechanical ventilation and these variations depend on the country [27,28]. That agrees with our study results where 35% of patients developed VAP in the follow-up period during their stay in the ICU. Also, it was documented in an Egyptian study done by Elkolaly et al. [29], the incidence of VAP was 38.4% in all patients admitted to ICU which is very close to our study results.

Some studies showed different results, The incidence of VAP in ICUs in China has been studied (26.85%) [30]. Ahmed et al. [31] found that VAP occurred at an incidence of 58.2% in three ICUs. This could be due to differences in the recording systems used in various hospitals. As regards the beneficial bacteria; both ICU patients and patients who developed HAIs (VAP) showed a statistically significant decrease in Bifidobacterium in comparison to the control group as well it was significantly lower in patients with a mortality rate ≥20% predicted hospital mortality and the control group.

Regarding bifidobacteria ,in addition to improving food absorption and preserving the integrity of the intestinal gut barrier, as well as immunological control and anticancer characteristics, bifidobacteria are one of the main bacteria that constitute the human gut microbiota [32,33]. Xu et al. [34] proved the bifidobacterial abundance as a part of prognosis prediction parameters plus APACHE II and Sequential Organ Failure Assessment (SOFA) score and it was found that Bifidobacterium abundance showed a significant reduction in the death group than the survival group. Therefore, this abundance showed good prognostic tools in predicting hospital mortality. As proven, gut microbiome disruptions and imbalance have been associated with many negative consequences such as VAP and increased re-infection and readmission as well, therefore administration of probiotics at admission with potential benefit to the host can balance the dysbiosis problems by reconstituting the gut microbiome as preventative and therapeutic approaches [35].

The limitation of our study was the small sample size because of implementing the inclusion criteria and strictly applying the exclusion criteria to selected patients as well financial issues that limit our study as a part of the international economic crisis, the import of such bacterial primers and reagents for quantitative real-time PCR is so much difficult and so expensive, especially in resource-limited countries. Also, our findings are limited to a single study center so further multicenter studies with larger sample sizes are recommended. At last, for ICU patients, it is not so that simple that they can pass stool in the first 24–72 hours following admission due to a change in bowel habits and diet.

This study focuses on the analysis of the gut microbiome profile for ICU patients at admission to correlate it with the development of HAIs so it can be used as a predictor for HAIs. It proved that gut dysbiosis at admission with a low F/B ratio is a marker for developing HAIs during ICU stay, therefore the patient can benefit from restoring the normal gut microbiome at admission to prevent the development of such infections and so ICU stay and mortality.

Probiotics is one method of restoring the normal gut microbiome that needs further studies to evaluate its efficiency in preventing HAIs in ICU patients at admission. Probiotics deserve all of this concern as it can replace the prophylactic antibiotics administered during admission and so reducing the risk of developing antibiotic resistance.

KEY MESSAGES

▪ Intensive Care Unit patients are at considerable risk of developing Healthcare-Associated infections (HAIs), so the gut microbiome analysis can be used to prevent or reduce the occurrence of HAIs and the spread of multidrug-resistant organisms.

▪ Profiling the pattern of gut microbiome at admission can be used as a predictor for HAIs for further manipulation.

NOTES

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization: SAE, SMA. Data curation: SMA, SAE, GMS, AME. Formal analysis: SMA, SLA, AME. Methodology: SE, SMA, SLA, AME. Writing–original draft: all authors. Writing–review & editing: all authors.

Acknowledgments

We are grateful to the molecular biology laboratory in the medical microbiology and immunology department. We thank all healthcare personnel who helped in the collection of samples from intensive care unit patients who enrolled in the study.

Figure 1.

Comparison between the studied groups according to gut microbiome. ICU: intensive care unit; N-HAI: negative for hospital associated infections; P-HAI: positive for hospital-associated infections.

Table 1.

Primers used in the present study

Target	Primer name	Primer sequence (5'-3')
Total bacteria	UnivF	TCCTACGGGAGGCAGCAGT
Total bacteria	UnivR	GGACTACCAGGGTATCTATCCTGTT
Akkermansia muciniphila	AM1-F	CAG CAC GTG AAG GTG GGG AC
Akkermansia muciniphila	AM2-R	CCT TGC GGT TGG CTT CAG AT
Bacteroides	B3F	CGATGGATAGGGGTTCTGAGAGGA
Bacteroides	B3R	GCTGGCACGGAGTTAGCCGA
Bacteroidetes	Bact934F	GGARCATGTGGTTTATTCGATGAT
Bacteroidetes	Bact1060R	AGCTGACGACAACCATGCAG
Bifidobacterium	Bif-F	TCGCGTC(C/T) GGTGTGAAAG
Bifidobacterium	Bif-R	CCACATCCAGC(A/G) TCCAC
Faecalibacterium prausnitzii	FPR-2F	GGAGGAAGAAGGTCTTCGG
Faecalibacterium prausnitzii	Fprau645R	AATTCCGCCTACCTCTGCACT
Firmicutes	Firm934F	GGAGYATGTGGTTTAATTCGAAGCA
Firmicutes	Firm1060R	AGCTGACGACAACCATGCAC
Lactobacilli	Lacto-F	AGCAGTAGGGAATCTTCCA
Lactobacilli	Lacto-R	CACCGCTACACATGGAG
Prevotella	PrevF	CACCAAGGCGACGATCA
Prevotella	PrevR	GGATAACGCCYGGACCT
Ruminococcus	Rflbr730F	GGCGGCYTRCTGGGCTTT
Ruminococcus	Clep866mR	CCAGGTGGATWACTTATTGTGTTAA

Table 2.

Comparison between the studied groups according to demographic data

Variable	ICU patient (n=20)	Control (n=30)	P-value
Sex			1.000
Male	8 (40.0)	12 (40.0)
Female	12 (60.0	18 (60.0)
Age (yr)			0.858
Mean±SD (range)	51.85±22.73 (18.0–80.0)	52.53±17.84 (23.0–81.0)
Median (IQR)	60.0 (29.0–68.0)	58.0 (32.0–64.0)
BMI (kg/m²)			0.797
Mean±SD (range)	28.27±2.90 (24.69–34.89)	28.77±5.31 (19.84–46.90)
Median (IQR)	27.73 (25.9–30.6)	27.33 (25.4–32.1)

Values are presented as number (%) or unless otherwise indicated.

ICU: intensive care unit; SD: standard deviation; IQR: interquartile range; BMI: body mass index.

Table 3.

Distribution of the studied cases according to clinical data of the ICU patients (n=20)

Admission diagnosis	Value
Cardiopulmonary disease	3 (15.0)
Cardiogenic shock	1 (5.0)
COPD	1 (5.0)
Myocardial infarction	1 (5.0)
Cerebrovascular accident	14 (70)
Drug intoxication	3 (15.0)
Noninfectious encephalopathy	1 (5.0)
Ischemic stroke	5 (25.0)
Epileptic seizures	1 (5.0)
RTA with head concussion	4 (20.0)
Others	3 (15)
Uremia	1 (5.0)
Hematemesis	1 (5.0)
Postoperative	1 (5.0)
APACHE II score
Mean±SD (range)	13.25±4.56 (7.0–21.0)
Median (IQR)	12.0 (9.0–17.0)
Type of devices
IVC	20 (100.0)
UC	20 (100.0)
CVC	15 (75.0)
MV	13 (65.0)

Values are presented as number (%) unless otherwise indicated.

ICU: intensive care unit; COPD: chronic obstructive pulmonary disease; RTA: road traffic accident; APACHE: Acute Physiology and Chronic Health Evaluation; SD: standard deviation; IQR: interquartile range; IVC: intravenous peripheral catheter; UC: urinary catheter; CVC: central venous catheter; MV: mechanical ventilation.

Table 4.

Comparison between the studied groups according to Gut microbiome

Gut microbiome	ICU patient (n=20)	Control (n=30)	P-value
Firmicutes	1.69E-1 (8.48E-2–3.41E-1)	4.95E-1 (4.18E-1–6.50E-1)	<0.001
Bacteroidetes	5.14E-1 (2.20E-1–7.14E-1)	3.45E-1 (2.31E-1–6.37E-1)	0.513
Prevotella	3.69E-3 (7.94E-4–1.20E-2)	4.62E-2 (1.74E-2–8.47E-2)	<0.001
Bacteroides	3.74E-1 (1.20E-1–6.53E-1)	1.09E-1 (6.50E-2–2.00E-1)	0.006
Ruminococcus	4.25E-3 (4.03E-4–3.81E-2)	4.67E-2 (2.05E-2–1.02E-1)	0.001
Bifidobacterium	2.03E-3 (4.67E-4–1.77E-2)	2.37E-2 (8.56E-3–5.05E-2)	0.003
Lactobacilli	1.92E-2 (2.59E-3–8.60E-2)	1.85E-3 (4.79E-4–3.44E-2)	0.025
Akkermansia muciniphila	2.20E-3 (2.54E-4–1.67E-1)	3.01E-3 (9.58E-4–1.84E-2)	0.828
Faecalibacterium	2.60E-3 (7.18E-5–2.22E-2)	2.15E-1 (7.95E-2–3.04E-1)	<0.001
Clostridioides difficile	0.00E+00 (0.00E+00)	0.00E+00 (0.00E+00)	-
F/B ratio	0.33 (0.25–1.76)	1.44 (0.90–2.18)	0.008
P/B ratio	0.02 (0.002–0.08)	0.26 (0.17–1.48)	<0.001
Diversity index	1.33 (1.15–1.46)	1.57 (1.52–1.66)	<0.001
Dissimilarity index	35.70 (26.0–53.45)	0.0 (0.0–0.0)	<0.001

Values are presented as median (interquartile range).

ICU: intensive care unit; F/B: Firmicutes/Bacteroidetes; P/B: Prevotella/Bacteroides.

Table 5.

Comparison between the two studied subgroups according to gut microbiome

Gut microbiome	P-HAI (n=8)	N-HAI (n=12)	Control (n=30)	Significance between groups
Firmicutes				P₁=0.759
Median	0.167	0.169	0.495	P₂=0.003
IQR	7.90E-2–2.98E-1	8.48E-2–4.47E-1	4.18E-1–6.50E-1	P₃=0.002^a)
Bacteroidetes				P=0.264
Median	0.63	0.374	0.345
IQR	4.19E-1–7.35E-1	1.20E-1–6.27E-1	2.31E-1–6.37E-1
Prevotella				P₁=0.405
Median	0.00818	0.0034	0.0462	P₂=0.022
IQR	8.12E-4–2.42E-2	7.94E-4–6.95E-3	1.74E-2–8.47E-2	P₃<0.001
Bacteroides				P₁=0.115
Median	0.569	0.167	0.109	P₂=0.002
IQR	3.07E-1–6.61E-1	7.43E-2–6.39E-1	6.50E-2–2.00E-1	P₃=0.138
Ruminococcus				P₁=0.456
Median	0.00362	0.00516	0.0467	P₂=0.003
IQR	6.34E-5–1.05E-2	7.27E-4–6.83E-2	2.05E-2–1.02E-1	P₃=0.016
Bifidobacterium				P₁=0.452
Median	0.000603	0.00254	0.0237	P₂=0.008
IQR	1.66E-4–1.70E-2	1.14E-3–1.96E-2	8.56E-3–5.05E-2	P₃=0.035
Lactobacilli				P=0.066^a)
Median	0.00457	0.0332	0.00185
IQR	1.51E-3–1.04E-1	1.05E-2–6.60E-2	4.79E-4–3.44E-2
Akkermansia muciniphila				P=0.152^a)
Median	0.0495	0.0022	0.00301
IQR	1.80E-4–2.48E-1	3.72E-4–2.93E-2	9.58E-4–1.84E-2
Faecalibacterium				P₁=0.970
Median	0.0031	0.00227	0.215	P₂<0.001
IQR	7.01E-5–1.06E-2	1.23E-4–3.18E-2	7.95E-2–3.04E-1	P₃<0.001
Clostridioides difficile				-
Median	0	0	0
IQR	0	0	0
F/B ratio				P₁=0.030
Median	0.31	0.83	1.44	P₂=0.001
IQR	0.15–0.73	0.29–3.55	10.90–2.18	P₃=0.274
P/B ratio				P₁=0.915
Median	0.03	0.02	0.26	P₂=0.002
IQR	0.002–0.13	0.003–0.08	0.17–1.48	P₃<0.001
Diversity index				P₁=0.456
Median	1.29	1.33	1.57	P₂=0.027
IQR	1.07–1.60	1.18–1.38	1.52–1.66	P₃<0.001
Dissimilarity index				P₁<0.001^a)
Median	28.90	41.75	0.0
IQR	25.50–44.50	30.20–58.95	0.0–0.0

P-HAI: positive for hospital-associated infections; N-HAI: negative for hospital-associated infections; IQR: interquartile range; P₁: P-value for comparing between P-HAI and N-HAI; P₂: P-value for comparing between P-HAI and Control; P₃: P-value for comparing between N-HAI and Control.

^a)P: P-value for comparing between the studied groups (If it was a significant value <0.05 ,test significance was done between subgroups, if not, P1, P2, and P3 were considered as <0.05).

Table 6.

Comparison between the studied groups according to enterotype

	ICU patient (n=20)	Control (n=30)	Monte Carlo P-value
Enterotype			0.017
1	19 (95.0)	18 (60.0)
2	1 (5.0)	9 (30.0)
3	0	3 (10.0)

Values are presented as number (%).

ICU: intensive care unit.

REFERENCES

1. Pettigrew MM, Johnson JK, Harris AD. The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Ann Epidemiol 2016;26:342-7.Article PubMed PMC
2. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010;182:1058-64.Article PubMed PMC
3. Petrof EO, Dhaliwal R, Manzanares W, Johnstone J, Cook D, Heyland DK. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 2012;40:3290-302.PubMed
4. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013;13:790-801.Article PubMed PMC PDF
5. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 2018;57:1-24.Article PubMed PMC PDF
6. Iacob S, Iacob DG, Luminos LM. Intestinal microbiota as a host defense mechanism to infectious threats. Front Microbiol 2019;9:3328. Article PubMed PMC
7. Chen Y, Zhang F, Ye X, Hu JJ, Yang X, Yao L, et al. Association between gut dysbiosis and sepsis-induced myocardial dysfunction in patients with sepsis or septic shock. Front Cell Infect Microbiol 2022;12:857035. Article PubMed PMC
8. Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. Article PubMed PMC PDF
9. Liu W, Cheng M, Li J, Zhang P, Fan H, Hu Q, et al. Classification of the gut microbiota of patients in intensive care units during development of sepsis and septic shock. Genomics Proteomics Bioinformatics 2020;18:696-707.Article PubMed PMC
10. Araos R, Tai AK, Snyder GM, Blaser MJ, D’Agata EM. Predominance of Lactobacillus spp. among patients who do not acquire multidrug-resistant organisms. Clin Infect Dis 2016;63:937-43.Article PubMed PMC
11. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009;360:20-31.Article PubMed
12. Singhi SC, Kumar S. Probiotics in critically ill children. F1000Res 2016;5:407. Article PubMed PMC PDF
13. Wagner DP, Draper EA. Acute physiology and chronic health evaluation (APACHE II) and Medicare reimbursement. Health Care Financ Rev 1984;(Suppl):91-105.PubMed PMC
14. El-Zawawy HT, Ahmed SM, El-Attar EA, Ahmed AA, Roshdy YS, Header DA. Study of gut microbiome in Egyptian patients with autoimmune thyroid diseases. Int J Clin Pract 2021;75:e14038.Article PubMed PDF
15. Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, et al. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav 2015;138:179-87.Article PubMed
16. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Cengage Learning; 2013.
17. Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948;27:379-423.Article
18. Bray JR, Curtis JT. An ordination of the upland forest communities of southern Wisconsin. Ecol Monogr 1957;27:326-49.Article PDF
19. Festi D, Schiumerini R, Birtolo C, Marzi L, Montrone L, Scaioli E, et al. Gut microbiota and its pathophysiology in disease paradigms. Dig Dis 2011;29:518-24.Article PubMed PDF
20. Alverdy JC, Krezalek MA. Collapse of the microbiome, emergence of the pathobiome, and the immunopathology of sepsis. Crit Care Med 2017;45:337-47.Article PubMed PMC
21. Song X, Chen Y, Li X. Differences in incidence and outcome of ventilator-associated pneumonia in surgical and medical ICUs in a tertiary hospital in China. Clin Respir J 2014;8:262-8.Article PubMed
22. Mariat D, Firmesse O, Levenez F, Guimarăes V, Sokol H, Doré J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009;9:123. Article PubMed PMC
23. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012;10:735-42.Article PubMed PDF
24. de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012;70 Suppl 1:S45-56.PubMed
25. Ojima M, Motooka D, Shimizu K, Gotoh K, Shintani A, Yoshiya K, et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci 2016;61:1628-34.Article PubMed PMC PDF
26. Iapichino G, Lankelma JM, Joost Wiersinga W. Gut microbiota disruption in critically ill patients : discussion on “Critically ill patients demonstrate large interpersonal variation of intestinal microbiota dysregulation: a pilot study”. Intensive Care Med 2017;43:718-9.Article PubMed PDF
27. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.Article PubMed
28. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med 2020;46:888-906.Article PubMed PMC PDF
29. Elkolaly RM, Bahr HM, El-Shafey BI, Basuoni AS, Elber EH. Incidence of ventilator-associated pneumonia: Egyptian study. Egypt J Bronchol 2019;13:258-66.Article PDF
30. Ojima M, Shimizu K, Motooka D, Ishihara T, Nakamura S, Shintani A, et al. Gut dysbiosis associated with antibiotics and disease severity and its relation to mortality in critically ill patients. Dig Dis Sci 2022;67:2420-32.Article PubMed PMC PDF
31. Ahmed NH, Hussain T, Biswal I. Antimicrobial resistance of bacterial isolates from respiratory secretions of ventilated patients in a multi-specialty hospital. Avicenna J Med 2015;5:74-8.Article PubMed PMC
32. Plantinga TS, van Maren WW, van Bergenhenegouwen J, Hameetman M, Nierkens S, Jacobs C, et al. Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. Clin Vaccine Immunol 2011;18:621-8.Article PubMed PMC
33. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9.Article PubMed PMC
34. Xu R, Tan C, Zhu J, Zeng X, Gao X, Wu Q, et al. Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death. Crit Care 2019;23:195. Article PubMed PMC PDF
35. Wolff NS, Hugenholtz F, Wiersinga WJ. The emerging role of the microbiota in the ICU. Crit Care 2018;22:78. Article PubMed PMC PDF

Figure & Data

References

Citations

Citations to this article as recorded by

Safety, feasibility, and impact on the gut microbiome of kefir administration in critically ill adults
Vinod K. Gupta, Sanu Rajendraprasad, Mahmut Ozkan, Dhanya Ramachandran, Sumera Ahmad, Johan S. Bakken, Krzysztof Laudanski, Ognjen Gajic, Brent Bauer, Simon Zec, David W. Freeman, Sahil Khanna, Aditya Shah, Joseph H. Skalski, Jaeyun Sung, Lioudmila V. Kar
BMC Medicine.2024;[Epub] CrossRef
Bringing gut microbiota into the spotlight of clinical research and medical practice
Efstathia Davoutis, Zoi Gkiafi, Panagis M Lykoudis
World Journal of Clinical Cases.2024; 12(14): 2293. CrossRef
Antimicrobial Peptides and Their Assemblies
Ana Maria Carmona-Ribeiro
Future Pharmacology.2023; 3(4): 763. CrossRef

PubReader

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Study of the gut microbiome as a novel target for prevention of hospital-associated infections in intensive care unit patients

Acute Crit Care. 2023;38(1):76-85. Published online February 23, 2023

DOI: https://doi.org/10.4266/acc.2022.01116

XML Download

Figure

Study of the gut microbiome as a novel target for prevention of hospital-associated infections in intensive care unit patients

Figure 1. Comparison between the studied groups according to gut microbiome. ICU: intensive care unit; N-HAI: negative for hospital associated infections; P-HAI: positive for hospital-associated infections.

Figure 1.

Study of the gut microbiome as a novel target for prevention of hospital-associated infections in intensive care unit patients

Target	Primer name	Primer sequence (5'-3')
Total bacteria	UnivF	TCCTACGGGAGGCAGCAGT
Total bacteria	UnivR	GGACTACCAGGGTATCTATCCTGTT
Akkermansia muciniphila	AM1-F	CAG CAC GTG AAG GTG GGG AC
Akkermansia muciniphila	AM2-R	CCT TGC GGT TGG CTT CAG AT
Bacteroides	B3F	CGATGGATAGGGGTTCTGAGAGGA
Bacteroides	B3R	GCTGGCACGGAGTTAGCCGA
Bacteroidetes	Bact934F	GGARCATGTGGTTTATTCGATGAT
Bacteroidetes	Bact1060R	AGCTGACGACAACCATGCAG
Bifidobacterium	Bif-F	TCGCGTC(C/T) GGTGTGAAAG
Bifidobacterium	Bif-R	CCACATCCAGC(A/G) TCCAC
Faecalibacterium prausnitzii	FPR-2F	GGAGGAAGAAGGTCTTCGG
Faecalibacterium prausnitzii	Fprau645R	AATTCCGCCTACCTCTGCACT
Firmicutes	Firm934F	GGAGYATGTGGTTTAATTCGAAGCA
Firmicutes	Firm1060R	AGCTGACGACAACCATGCAC
Lactobacilli	Lacto-F	AGCAGTAGGGAATCTTCCA
Lactobacilli	Lacto-R	CACCGCTACACATGGAG
Prevotella	PrevF	CACCAAGGCGACGATCA
Prevotella	PrevR	GGATAACGCCYGGACCT
Ruminococcus	Rflbr730F	GGCGGCYTRCTGGGCTTT
Ruminococcus	Clep866mR	CCAGGTGGATWACTTATTGTGTTAA

Variable	ICU patient (n=20)	Control (n=30)	P-value
Sex			1.000
Male	8 (40.0)	12 (40.0)
Female	12 (60.0	18 (60.0)
Age (yr)			0.858
Mean±SD (range)	51.85±22.73 (18.0–80.0)	52.53±17.84 (23.0–81.0)
Median (IQR)	60.0 (29.0–68.0)	58.0 (32.0–64.0)
BMI (kg/m²)			0.797
Mean±SD (range)	28.27±2.90 (24.69–34.89)	28.77±5.31 (19.84–46.90)
Median (IQR)	27.73 (25.9–30.6)	27.33 (25.4–32.1)

Admission diagnosis	Value
Cardiopulmonary disease	3 (15.0)
Cardiogenic shock	1 (5.0)
COPD	1 (5.0)
Myocardial infarction	1 (5.0)
Cerebrovascular accident	14 (70)
Drug intoxication	3 (15.0)
Noninfectious encephalopathy	1 (5.0)
Ischemic stroke	5 (25.0)
Epileptic seizures	1 (5.0)
RTA with head concussion	4 (20.0)
Others	3 (15)
Uremia	1 (5.0)
Hematemesis	1 (5.0)
Postoperative	1 (5.0)
APACHE II score
Mean±SD (range)	13.25±4.56 (7.0–21.0)
Median (IQR)	12.0 (9.0–17.0)
Type of devices
IVC	20 (100.0)
UC	20 (100.0)
CVC	15 (75.0)
MV	13 (65.0)

Gut microbiome	ICU patient (n=20)	Control (n=30)	P-value
Firmicutes	1.69E-1 (8.48E-2–3.41E-1)	4.95E-1 (4.18E-1–6.50E-1)	<0.001
Bacteroidetes	5.14E-1 (2.20E-1–7.14E-1)	3.45E-1 (2.31E-1–6.37E-1)	0.513
Prevotella	3.69E-3 (7.94E-4–1.20E-2)	4.62E-2 (1.74E-2–8.47E-2)	<0.001
Bacteroides	3.74E-1 (1.20E-1–6.53E-1)	1.09E-1 (6.50E-2–2.00E-1)	0.006
Ruminococcus	4.25E-3 (4.03E-4–3.81E-2)	4.67E-2 (2.05E-2–1.02E-1)	0.001
Bifidobacterium	2.03E-3 (4.67E-4–1.77E-2)	2.37E-2 (8.56E-3–5.05E-2)	0.003
Lactobacilli	1.92E-2 (2.59E-3–8.60E-2)	1.85E-3 (4.79E-4–3.44E-2)	0.025
Akkermansia muciniphila	2.20E-3 (2.54E-4–1.67E-1)	3.01E-3 (9.58E-4–1.84E-2)	0.828
Faecalibacterium	2.60E-3 (7.18E-5–2.22E-2)	2.15E-1 (7.95E-2–3.04E-1)	<0.001
Clostridioides difficile	0.00E+00 (0.00E+00)	0.00E+00 (0.00E+00)	-
F/B ratio	0.33 (0.25–1.76)	1.44 (0.90–2.18)	0.008
P/B ratio	0.02 (0.002–0.08)	0.26 (0.17–1.48)	<0.001
Diversity index	1.33 (1.15–1.46)	1.57 (1.52–1.66)	<0.001
Dissimilarity index	35.70 (26.0–53.45)	0.0 (0.0–0.0)	<0.001

Gut microbiome	P-HAI (n=8)	N-HAI (n=12)	Control (n=30)	Significance between groups
Firmicutes				P₁=0.759
Median	0.167	0.169	0.495	P₂=0.003
IQR	7.90E-2–2.98E-1	8.48E-2–4.47E-1	4.18E-1–6.50E-1	P₃=0.002^a)
Bacteroidetes				P=0.264
Median	0.63	0.374	0.345
IQR	4.19E-1–7.35E-1	1.20E-1–6.27E-1	2.31E-1–6.37E-1
Prevotella				P₁=0.405
Median	0.00818	0.0034	0.0462	P₂=0.022
IQR	8.12E-4–2.42E-2	7.94E-4–6.95E-3	1.74E-2–8.47E-2	P₃<0.001
Bacteroides				P₁=0.115
Median	0.569	0.167	0.109	P₂=0.002
IQR	3.07E-1–6.61E-1	7.43E-2–6.39E-1	6.50E-2–2.00E-1	P₃=0.138
Ruminococcus				P₁=0.456
Median	0.00362	0.00516	0.0467	P₂=0.003
IQR	6.34E-5–1.05E-2	7.27E-4–6.83E-2	2.05E-2–1.02E-1	P₃=0.016
Bifidobacterium				P₁=0.452
Median	0.000603	0.00254	0.0237	P₂=0.008
IQR	1.66E-4–1.70E-2	1.14E-3–1.96E-2	8.56E-3–5.05E-2	P₃=0.035
Lactobacilli				P=0.066^a)
Median	0.00457	0.0332	0.00185
IQR	1.51E-3–1.04E-1	1.05E-2–6.60E-2	4.79E-4–3.44E-2
Akkermansia muciniphila				P=0.152^a)
Median	0.0495	0.0022	0.00301
IQR	1.80E-4–2.48E-1	3.72E-4–2.93E-2	9.58E-4–1.84E-2
Faecalibacterium				P₁=0.970
Median	0.0031	0.00227	0.215	P₂<0.001
IQR	7.01E-5–1.06E-2	1.23E-4–3.18E-2	7.95E-2–3.04E-1	P₃<0.001
Clostridioides difficile				-
Median	0	0	0
IQR	0	0	0
F/B ratio				P₁=0.030
Median	0.31	0.83	1.44	P₂=0.001
IQR	0.15–0.73	0.29–3.55	10.90–2.18	P₃=0.274
P/B ratio				P₁=0.915
Median	0.03	0.02	0.26	P₂=0.002
IQR	0.002–0.13	0.003–0.08	0.17–1.48	P₃<0.001
Diversity index				P₁=0.456
Median	1.29	1.33	1.57	P₂=0.027
IQR	1.07–1.60	1.18–1.38	1.52–1.66	P₃<0.001
Dissimilarity index				P₁<0.001^a)
Median	28.90	41.75	0.0
IQR	25.50–44.50	30.20–58.95	0.0–0.0

	ICU patient (n=20)	Control (n=30)	Monte Carlo P-value
Enterotype			0.017
1	19 (95.0)	18 (60.0)
2	1 (5.0)	9 (30.0)
3	0	3 (10.0)

Table 1. Primers used in the present study

Table 2. Comparison between the studied groups according to demographic data

Values are presented as number (%) or unless otherwise indicated.

ICU: intensive care unit; SD: standard deviation; IQR: interquartile range; BMI: body mass index.

Table 3. Distribution of the studied cases according to clinical data of the ICU patients (n=20)

Values are presented as number (%) unless otherwise indicated.

Table 4. Comparison between the studied groups according to Gut microbiome

Values are presented as median (interquartile range).

ICU: intensive care unit; F/B: Firmicutes/Bacteroidetes; P/B: Prevotella/Bacteroides.

Table 5. Comparison between the two studied subgroups according to gut microbiome

P: P-value for comparing between the studied groups (If it was a significant value <0.05 ,test significance was done between subgroups, if not, P1, P2, and P3 were considered as <0.05).